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Summary Several different drug retreatment protocols were employed to examine the emergence of
resistance to MeCCNU in Lewis lung tumours. Previous studies suggested that although the majority of cells
in untreated Lewis lung tumours were sensitive to MeCCNU, there was a very small proportion of resistant
cells (-0.001%) that limited 'tumour cure' with that drug. If such cells were inherently drug resistant then it
should be possible to derive highly resistant tumours by repeated drug treatment.
In the first experiment tumours were treated with a single high dose of MeCCNU (35 or 40mgkg-1) and
on regrowth, transplanted into fresh mice and tested for drug sensitivity. Using both excision cell survival and
growth delay endpoints, only 25% of tumours were significantly resistant to the test dose, suggesting that
many tumours resist the effects of the drug for reasons other than the presence of inherently drug resistant
cells. One of the tumours (R4), that regrew after the initial treatment and appeared to be resistant to the test
treatment, was retreated with a further 30mgkg-1 MeCCNU and became more resistant. This line,
designated R4/1, was cross-resistant to the other nitrosoureas, BCNU and CCNU, but not to cyclophospha-
mide, melphalan, cis-platinum or ionising radiation.
The effect of treatment dose on the kinetics of MeCCNU resistance development was also studied in a
retreatment regimen where the tumours were allowed to regrow and then transplanted into fresh hosts for the
next treatment. Resistance developed more quickly at an intermediate dose of 15mgkg-1 than at 7.5mgkg-1
where the selective pressure was lower, or at 30mgkg-1 where there was probably extinction of partially
resistant cells.
Resistance to MeCCNU developed even more quickly when tumours were retreated several times in the
same host, although in a similar experiment with cyclophosphamide no resistance occurred.
In a recent publication we presented data showing
that, although previously untreated Lewis lung
tumours appeared to be very sensitive to the
cytotoxic nitrosourea MeCCNU using a clonogenic
cell survival endpoint, they infact contained a very
small subpopulation of cells that were highly
resistant to this agent (Stephens et al., 1984).
In excision cell survival studies, a steep
exponential curve (D1O=2mgkg-1) extending
down to nearly 5 decades (the limit of sensitivity of
the assay) was observed, and it appeared that
tumours should be easily cured by MeCCNU doses
in the order of 15mgkg-1. This is only 40% of
the LD10 (lethal dose to 10% of animals) in our
C57B1 mouse strain. However, in tumour cure
experiments, no cures could be obtained at the
predicted dose level, although some tumours were
cured at doses approaching the LD10. Futhermore,
the regrowth delay curve was biphasic with drug
dose: at doses up to 15 mgkg-1 the extent of
growth delay increased rapidly, while at higher
doses the rate of increase in growth delay was much
less.
These observations are all consistent with the
hypothesis that Le#is lung tumours contain a very
small subpopulation of drug resistant cells. To
investigate this prediction, an experiment was
designed in which gamma irradiation was used to
'top-up' the effect of various doses of MeCCNU
and tumour cure rates were determined. From the
doses of radiation that were needed to cure 50% of
tumours that had previously received MeCCNU,
cell survival after very large doses of MeCCNU
could be predicted by making reasonable
assumptions about the clonogenic cellularity of
tumours and the radiosensitivity of the cells
surviving MeCCNU treatment. This led to the
construction of a cell survival curve at doses
beyond those that could be examined directly by
the excision cell survival endpoint, and suggested
that previously untreated Lewis lung tumours
contained a subpopulation of ceils comprising
about 0.001%, that were -10 times more resistant
(DIO=20mgkg-1) than the majority of tumour
cells.
In this paper we have extended the above studies
by attempting to explore the natu. of the
resistance to MeCCNU. From our previous work it
is not clear whether resistance reflects an intrinsic
cellular biochemical property within a sub-
population of tumour cells, or extrinsic factors such
as cellular environment are involved.
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To investigate these possibilities we have used
several different drug treatment protocols in an
attempt to select intrinsically resistant cells that
may be present within Lewis lung tumours. We
have also partially characterised one of the
resultant tumour lines with respect to its sensitivity
to other cytotoxic drugs and radiation. The precise
kinetics of emergence of cytotoxic drug resistance
during treatment of tumours in vivo has not been
widely explored, although we recently reported the
kinetics of development of resistance to cyclo-
phosphamide, melphalan and cis-platinum, in the
murine MT carcinoma model (McMillan et al.,
1985).
Materials and methods
Mice and tumour
Wild-type Lewis lung (LL) carcinoma and the
sublines derived in this study, were maintained by
i.m. transplantation of 0.5ml of 1:5 diluted tumour
brei, into the gastrocnemius muscles of 20 to 25g
C57BI/Cbi mice obtained from the Institute of
Cancer Research breeding colony. For experiments,
either i.m. tumours in the leg or s.c. tumours in the
flank were used when they weighed between 0.15
and 0.25g.
Drug and radiation treatments
The suppliers, preparation and i.p. administration
to mice of MeCCNU, CCNU, BCNU, cyclophos-
phamide (CY), melaphalan and cis-dichloro-
diammine platinum (cis-Pt) have all been described
in previous publications (Rose et al., 1980; Stephens
& Peacock, 1978; Stephens et al., 1984).
In experiments on tumour cell radiosensitivity,
tumour bearing mice were irradiated to the whole
body at a dose rate of approximately 3Gymin-1,
using a dedicated 2000Ci tele-cobalt unit (Stephens
et al., 1978). In all cases, tumours were excised for
clonogenic assay immediately after irradiation. To
determine the hypoxic response of tumour cells,
tumour bearing mice were killed 10min before
irradiation.
Measurement oftumour cell survival
Tumour cell suspensions for in vitro cell survival
assays were prepared by trypsinisation of aseptically
excised tumour tissue (Stephens & Peacock, 1978).
In this series of experiments the viable yield of
tumour cells from previously untreated LL
tumours, assessed by haemocytometer, was
- 8 x 107cellsg-1. The yields of tumour cells
obtained from tumour sublines selected by
MeCCNU treatment did not differ significantly
from this value.
Tumour cell survival was measured by cloning in
soft-agar (Courtenay, 1976). In a previous publi-
cation (Stephens et al., 1978) we noted that LL
tumour cell suspensions usually contain significant
proportions (- 15%) of host cells which can form
morphologically distinct colonies in agar. When
counting cell suspensions and culture dishes, care
was taken to discriminate between tumour and host
cells and colonies.
In these experiments the mean tumour cell
plating efficiency (PE=number of tumour colonies
scored/number of tumour cell plated) of untreated
controls was about 0.5, and did not vary
significantly between the parent tumour and its
sublines.
The effect of drug treatment was expressed as the
'surviving fraction per tumour' (SF per
tumour=number of colony forming cells per
treated tumour/number of colony forming cells per
control tumour). This parameter takes into account
drug induced changes in tumour cell yield as part
of the overall effect of treatment.
Measurement oftumour regrowth delay
The method of evaluating the weight of treated and
control i.m. tumours for regrowth delay studies was
described in detail by Stephens et al. (1984). Since
at low drug doses tumours often did not shrink
below their treatment volume, the response of each
individual tumour was evaluated as the time to
grow to 4 x its size at the time of treatment (T4 x).
The behaviour of groups of identically treated
tumours was expressed as median T4 x with 25th
and 75th percentiles. Growth delay was calculated
as: (median T4 x of treated tumours) - (median
T4 x ofuntreated controls).
Lung cloning
Lung colonies were produced by i.v. injection via
the tail vein of 104 to 105 viable LL cells derived by
trypsinisation, together with 106 radiation killed LL
cells and 106 15pm diameter plastic microspheres.
Macroscopic lung colonies were produced in 2 to 3
weeks.
Results
Selection ofdrug resistant sublines
In order to determine whether previously untreated
LL tumours contained a subpopulation of cells that
were inherently resistant to MeCCNU, tumours
that had regrown after a high drug dose were re-
examined for MeCCNU sensitivity. The treatment
should have preferentially killed the drug sensitive
cells, leading to enrichment of the resistant sub-
population, and development of a resistant tumour.EMERGENCE OF NITROSOUREA RESISTANT TUMOUR LINES
In the first experiment, four i.m. tumours which
regrew following treatment with 40mgkg-1
MeCCNU, were each transplanted into 20 mice.
When these tumours had grown to a size of 0.2g,
they were then again treated with MeCCNU at a
range of doses, and excision cell survival and
growth delay were both measured. Figures 1 and 2
show that three of these tumours (designated RI,
R2, and R3), which had resisted high-dose
MeCCNU, were at least as sensitive as wild-type
tumours (wild-type LL response curves are shown
dashed in the figures), although the fourth tumour
(R4), was significantly more resistant. R4 had an
increased D10 of 4.9mgkg-1 (compared to
2mgkg-1 for wild-type LL), and the resistant tail
on the growth delay curve was more apparent.
There was also a suggestion that R3 may be more
sensitive to MeCCNU than wild-type LL, as
indicated by the growth delay endpoint.
Two tumours derived from R4, were treated for a
second time with 30mgkg-1 MeCCNU, and on
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Figure 1 In vivo survival curves to MeCCNU of
tumour lines that had regrown after MeCCNU
treatment. Ten 0.2gLL tumours were treated with
40mgkg-1 MeCCNU, and 4 of those that regrew
(RI 0, R2 El, R3 A, R4 *) were each passaged into
fresh mice. When those tumours reached 0.2g, they
were treated with graded doses of MeCCNU and 24h
later an excision cell survival assay was performed.
One line (R4) was also treated for a second time with
30mgkg-1 and two regrowers (R4/1 A, R4/2 0) were
tested for MeCCNU sensitivity by cell survival assay.
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Figure 2 Growth delay curves to MeCCNU of
tumour lines that had regrown after MeCCNU
treatment. See Figure 1 for details of the derivation of
tumour lines. Error bars are the 25 and 75 percentiles
of the median value.
regrowth they were re-passaged into fresh mice to
yield sub-lines R4/1 and R4/2. When these lines
were tested again for MeCCNU sensitivity, there
was a further increase in the degree of resistance,
seen as reduced survival curve slope (R4/1 terminal
DIO=8.6mgkg-1) and the appearance of a
shoulder (n=3.5, Figure 1) and a reduction in
growth delay (Figure 2). Line R4/1 has retained its
resistant characteristics for more than 50 passages
without further treatment.
In order to confirm these results, a second
experiment utilizing only growth delay was
performed. The results are shown in Table I. Again,
most of the tumours (5/7) which regrew after
30mgkg-1 MeCCNU were as sensitive, or more
sensitive than wild-type LL, when transplanted and
tested in fresh mice. In addition, four tumours
transplanted from RIO (which were at least as
sensitive to MeCCNU as wild-type LL), were
retreated with 30mgkg-1 MeCCNU, allowed to
regrow, transplanted and re-tested (RIO/I, RIO/2,
RlO/3, RIO/4). They were found to be mostly
sensitive (3/4), although one was highly resistant.
From these results it seems that - 75% of
tumours regrowing after high-dose MeCCNU
treatment are as drug sensitive as wild-type LL, and
that MeCCNU resistance in previously untreated
LL tumours cannot be simply explained by the
presence of a minority of inherently resistant cells,
unless these cells reverted to a sensitive phenotype
after the initial selection. However, some tumours
obviously do resist the effects of MeCCNU due to
the presence ofinherently resistant cells.
MeCCNU resistance in clonal LL lines
An experiment was performed to investigate
whether clonal LL lines had the same sensitivity to
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Table I Growth delay response of LL lines previously
treated with one or two high doses of MeCCNU
Growth delayfor
Line Previous MeCCNU 25mgkg-1 MeCCNU
designation treatment' (days)
Wild-type LL None 15 (13-l9)b
R10 30mgkg-1 22.7
Rll 30mgkg-1 18.3
R12 30mgkg-1 16.9
R13 30mgkg-1 13.8
R14 30mgkg-1 9.5
R15 30mgkg-1 26.8
R16 30mgkg-1 9.2
R1O/I 30mgkg-1, 30mgkg-1 6.7
R10/2 30mgkg-1, 30mgkg-1 20.0
R10/3 30mgkg-1, 30mgkg-1 21.0
R10/4 30mgkg-1, 30mgkg-1 26.4
aIndividual tumours that had regrown after treatment
with 30mgkg-1 MeCCNU were transplanted bilaterally
i.m. into groups of five mice. When the tumours reached
about 0.2g they were treated with a test dose of
25mgkg-1 MeCCNU and the median growth delay was
measured. Line RIO was also transplanted and treated
with a second 30mgkg-1 MeCCNU dose, and then tested
with 25mgkg-1.
bMedian growth delay with 25th and 75th percentiles.
MeCCNU as the wild-type highly passaged tumour.
Clonal lines might be more drug sensitive if they
did not contain inherently resistant cells. This might
be so if resistant cells arise with low incidence and
are present in wild-type tumour because they are
passaged from tumour to tumour during trans-
plantation.
Six clonal LL lines were selected as lung
colonoies following i.v. tail vein implantation of
tumour cells. The lung colonies were dissected from
the lungs when they were 2mm in diameter and
transplanted first s.c. in the flank, then i.m. in the
leg, prior to treatment with MeCCNU. A single
large test treatment of 35mgkg-1 was used to
reveal drug resistance. Tumours containing only
sensitive cells should be easily cured at this dose,
but no cures were achieved, and the median growth
delays for the clones (15.8, 22.5, 21.1, 14.5, 19.8,
and 16.6 days) were not significantly different from
wild-type tumours.
Multiple retreatments with MeCCNU in different
mice
Although the tumour lines developed following one
or two treatments with high dose MeCCNU, were
substantially more drug resistant than wild-type
LL, they were not totally drug resistant. An
experiment was therefore performed to establish
whether even greater resistance would develop if
many more treatments were administered. In this
study the dose per treatment was also varied.
In the initial experiment five mice bearing
bilateral 0.2g s.c. tumours were treated with
15mgkg-1 MeCCNU and growth delay was
measured. The first tumour to regrow to 4 x
treatment size was transplanted into ten fresh mice,
and on reaching 0.2g was again treated with
15mgkg-t MeCCNU and growth delay measured.
This procedure was repeated nine times,
whereupon, the tumour had become highly drug
resistant, as indicated by negligible regrowth delay
(Figure 3, closed symbols). In fact, it appeared that
the resistance was already near its maximum after
only five MeCCNU retreatments, and at this point,
a second tumour line was established which was
passaged without further treatment in order to
observe the stability of resistance. This line was
tested for MeCCNU sensitivity every few passages
and retained the resistance that it had initially
developed in the five treated passages (Figure 3,
open symbols).
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Figure 3 Development of MeCCNU resistance by
drug retreatment, with transplantation into fresh mice.
Mice bearing s.c. LL tumours were treated with
15mgkg-1 MeCCNU and the first tumour to regrow
was passaged into fresh mice. These mice were then
retreated with MeCCNU and the first regrower was
again selected for transplantation. This procedure was
repeated in 8 consecutive passages (i.e. 9 treatments)
and the median regrowth time for each batch of
tumours is shown as solid symbols. At passage 4 (i.e.
after 5 treatments), a second tumour line was passaged
without further treatment, but was occasionally tested
for MeCCNU sensitivity (open symbols). Error bars as
in Figure 2.
In a second experiment three different doses of
MeCCNU were used to retreat tumours (7.5, 15
and 30mgkg-1), in order to study the rate of
resistance induction as a function of drug dose.
Figure 4A shows the changes in growth delay with
treatment at the three dose levels. Although it
appeared that resistance developed faster at lower
doses than at higher doses (more treatments wereEMERGENCE OF NITROSOUREA RESISTANT TUMOUR LINES 241
unrealistic compared to the clinical situation where
a tumour is repeatedly treated within the same host.
The outcome of the above experiments might be
influenced by the need to transplant tumour
between treatments. The most likely problem is that
at the start of a retreatment protocol we may, by
transplanting only a small amount of tumour
tissue, fail to include resistant cells, and thereby
underestimate the true rate of resistance develop-
ment.
An experiment was therefore designed to study
the development of MeCCNU resistance within a
single mouse. Figure 5A shows the median
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Figure 4 Effect of dose on the rate of development of
MeCCNU resistance in a multiple drug retreatment/
transplantation regimen. The procedure to develop
drug resistance is the same as that described in the
legend for Figure 3. (a) This shows the changes in
growth delay incurred by repeated treatments with
MeCCNU at 30(g), 15(0) or 7.5mgkg-1(A). (b)
From the data in (a) it is difficult to determine the
rates of resistance development at the different dose
levels, because the initial growth delay varies widely.
Thus, tumours that had been retreated repeatedly with
7 5(A) or 30mgkg-1(El) MeCCNU were tested in
thb next passage with 15mgkg1, and this data was
compared with 15mgkg1 (0) retreatments. Error
bars as in Figure 2.
required to reduce growth delay to a low value),
this may be misleading because the extent of change
in growth delay varies with dose. To overcome this
problem, tumours lines that had been retreated with
7.5 or 30mgkg-1 were each tested in the next
passage with 15mgkg-1, so that they could be
directly compared with the 15mgkg-1 data. Figure
4B then shows that resistance induction was slightly
slower at both 7.5 and 30 mgkg1, than at
15mgkg-1.
Multiple retreatments with MeCCNU in the same
mouse
The above experiments were performed by
repeatedly transplanting tumours that had regrown
following MeCCNU treatment, into fresh mice for
the next cycle of treatment. However, this is
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Figure 5 Development of drug resistance by retreat-
ment in the same mouse. Five groups of 5 mice each
bearing bilateral s.c. LL tumours were prepared. One
served as untreated control and the other four were
treated either with MeCCNU or CY. Tumour volume
was measured regularly in all groups, and when the
treated tumours had regrown to pretreatment volume
three groups were again treated and the others
measured to define the untreated growth, and treated
regrowth curves. The treatment procedure was
repeated up to three more times giving the next
treatment as soon as the tumours had begun to
regrow. (a) Development of resistance with three
15mgkg-' doses of MeCCNU. The tumours were too
big after three treatments for the fourth to be given,
however, resistance was almost complete as judged by
the lack of tumour volume response with the third
treatment. (b) Failure to develop resistance with four
200mgkg-1 doses of CY. For clarity, error bars are
not shown, but they were always within the range
+25% of median tumour weight.
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regrowth curve of ten s.c. LL tumours, treated
once, twice or three times with 15mgkg-1
MeCCNU, by which time they appeared to be
totally drug resistant (growth delay had decreased
as follows, 14, 6.9, 0.6 days). For comparison, LL
tumours retreated up to four times with
200mgkg-1 CY (Figure SB) had not developed
any drug resistance as indicated by consistent levels
of growth delay (11.35, 8.6, 11, and 9.9 days).
Cross-resistance to other drugs and radiation
Lastly, experiments were perfoimed to characterise
one of the MeCCNU resistant lines (R4/1) for
cross-resistance to some other related nitrosoureas,
and commonly used cytotoxic agents.
Table II summarises the results of excision cell
survival experiments to compare the sensitivity of
R4/1, and wild-type LL. Drug sensitivity was
expressed in terms of survival curve slope, with
extent of cross-resistance indicated by the ratio:
(R4/1 curve slope)/(LL curve slope).
Table II Sensitivities of LL and R4/1
cytotoxic drugs
to various
DIOM (mgkg-1)
Drug LL R4/1 DJO ratio
MeCCNU 1.8 9.2 5.1
CCNU 3 11 3.7
BCNU 12 59 4.9
CY 30 30 1.0
Melphalan 7.5 7.5 1.0
Cis-Pt 3 3 1.0
aSlope of the survival curve expressed as drug dose to
reduce cell survival by 1 decade.
As might be expected, tumour line R4/1 was
cross-resistant (as indicated by a ratio that was > 1)
to the other nitrosoureas CCNU and BCNU, but
not (ratio= 1) to the alkylating agents CY and
melphalan, or the DNA cross-linking cis-Pt.
There was also no difference in the response of
R4/1 and LL to ionising radiation as judged by
excision cell survival immediately following acute
treatment under either air-breathing or hypoxic
conditions (data not shown). In each case, the Do
of hypoxic tumour cells was - 3.2Gy, with an
extrapolation number (n) of 8, and the hypoxic
fraction of tumours in air-breathing mice was 10%.
Discussion
In this paper we have demonstrated that some
tumours that regrow after high, theoretically
curative, doses of MeCCNU contain cells that are
inherently resistant to the drug. The resistant cells
were revealed by several different retreatment
regimes designed to selectively kill MeCCNU
sensitive tumour cells, and to lead to the selection
of highly resistant tumour cell populations that
retained resistance during passage without further
treatment. A similar phenomenon has been
described previously by Griswold (1974), who
developed a line of B16 melanoma that was highly
resistant to MeCCNU after only three retreatments,
but he did not explore the kinetics of resistance
development as described here.
However, in our studies, only a minority (-25%)
of tumours that regrew following treatment with
single high MeCCNU doses (30-40mgkg-1) that
should have killed the drug sensitive cells, were
subsequently found to retain resistance to a second
test treatment. These resistant tumours presumably
contained an enriched proportion of inherently
resistant cells that could be selected further by
additional treatment, although some other
mechanism must be responsible for resistance in the
majority of singly treated tumours that should have
been cured if they consisted only of drug sensitive
cells. Although inherently sensitive cells might be
protected in kinetic, pharmacological or environ-
mental sanctuaries, the apparent rarity of such
sanctuaries makes this suggestion, to us, unlikely.
Only 1 in 105 tumour cells are resistant according
to the survival curve published in our previous
paper (Stephens et al., 1984) and this is supported
by growth delay data. The growth delays for wild-
type and sensitive tumour lines treated with
25mgkg-I MeCCNU were 15 to 20 days (Table I)
and assuming a 1 day doubling time for surviving
cells, this translates into 5 to 6 decades of cell
killing.
The experiments presented here were specifically
designed to explore the kinetics of development of
cytotoxic drug resistance, following the interest
shown in the work of Goldie & Coldman (1979) on
the possible emergence of drug resistant cells in
tumours as the result of spontaneous mutation, and
the subsequent selection of resistant cells that will
occur with continued treatment (Skipper et al.,
1978). Some of the limitations of these ideas have
been discussed in a previous paper (McMillan et
al., 1985).
The development of resistance to nitrosoureas is
especially interesting because one of the principal
mechanisms has been determined at the molecular
level. This is the increased capacity of some cells to
repair lesions in their DNA, by the specific removal
of alkyl groups from the 06 position of guanine
residues of DNA, due to the presence of increased
levels of the receptor protein 06-methyl guanine-
DNA methyltransferase (Harris et al., 1983; Yarosh
et al., 1983). The primary site of interactionEMERGENCE OF NITROSOUREA RESISTANT TUMOUR LINES 243
between monofunctional nitrosoureas and DNA is
apparently the 06 position of guanine, and bifunc-
tional nitrosoureas appear first to react with this
site, and later to react again either with DNA or
protein to form cross-links. Removal of the mono-
adduct from the DNA prevents the apparently
lethal cross-linking step (Erickson et al., 1980;
Meyn et al., 1982; Robins et al., 1983; Brent, 1984).
We have evidence that MeCCNU resistance in our
line R4/1 involves increased levels of 06-methyl-
guanine-DNA methyltransferase (in preparation).
The kinetics of development of MeCCNU
resistance during retreatment regimes involving
transplantation into fresh hosts between drug doses
is fairly well defined by our data, although there
are several complicating factors in the interpretation
of Figures 3 and 4. At an intermediate drug dose
of 15mgkg-1, tumours appeared to be equally
sensitive to the first two drug doses using a median
growth delay endpoint. Since this MeCCNU dose
apparently killed -6 decades of sensitive tumour
cells and the tumour only started with around 108
clonogenic cells, then some enrichment of pre-
existing resistant cells might have been expected
due to the selective pressure of the first treatment,
making the second dose less effective. However, the
resistant cells are not totally resistant, and the
initial population could have been reduced by about
1 decade, perhaps enough to destroy all resistant
cells in some tumours (we call this phenomenon
'extinction'). Wide variations in the numbers of
resistant cells within individual tumours is predicted
by Goldie & Coldman (1979), as a consequence of
spontaneous mutation to the resistant phenotype.
Alternatively resistance may develop more slowly if
resistant cells were lost during transplantation
between treatments due to inadequate sampling.
This is possible because in our transplantation
protocol we only transfer 106 viable cells. Also,
the development of resistance could differ if the
growth rate of sensitive and resistant cells was not
the same. Small differences in cell doubling times
during tumour regrowth and after transplantation
could change the ratio of sensitive to resistant cells
present at the next treatment. Although there was
no suggestion of this from the shapes of tumour
growth curves during retreatment protocols that
produced highly resistant tumours, resistant line
R4/1 does grow marginally faster than wild-type LL.
At the higher MeCCNU dose of 30mgkg1 a
greater proportion of sensitive cells should be killed
with each dose, but also more resistant cells should
be killed, with a greater probability of their
extinction. Thus, the development of resistance
could be delayed (Figure 4B). The lower dose
(7.5mgkg-1) should kill fewer tumour cells and
resistant tumours would be expected to take longer
to emerge under the lower selective pressure (Figure
4B).
There is reason to believe that the above
assumption (based on Goldie & Coldman, 1979)
that MeCCNU resistant cells can emerge as a result
of spontaneous mutation during the course of
tumour growth is more likely than the alternative
suggestion, that a preexisting population of
resistant cells is transplanted from passage to
passage. Clonal LL lines were found to be no
different in sensitivity to MeCCNU than the highly
passaged wild-type tumour and some must have
contained a small proportion of resistant cells that
had developed during growth from a single cell.
Conclusive evidence for this has been obtained by
McMillan (1985), who derived four clonal LL lines,
and each became highly, and permanently resistant,
following four retreatments with 15mgkg-
MeCCNU.
Another mechanism that could conceivably be
involved in the acquisition of permanent drug
resistance, is the induction of mutations by the first
treatment with a drug, that confers resistance to
subsequent treatments with the same drug. We are
not aware that this has ever been demonstrated
with a cytotoxic drug, although we have enhanced
the induction of resistance to CY in MT carcinoma
by pretreatment of the tumour cells with the
classical mutagen ethyl methanesulphonate
(McMillan et al., 1985). MeCCNU and other nitro-
soureas are significantly mutagenic in the Ames
Salmonella typhimurium assay (Franza et al.,
1980), and in chinese hamster cells, at the HGPRT
locus as 6-thioguanine resistance (Bradley et al.,
1980). However, the likelihood that a specific
mutation conferring resistance to MeCCNU should
occur in the small population of survivors from
high-dose MeCCNU seems slim. Nevertheless, this
could explain the delayed development of resistance
to MeCCNU until at least two drug treatments had
been given (Figures 3 and 4).
Although MeCCNU resistance developed quite
quickly in the retreatment experiments involving
transplantation, it developed even more quickly
when treatments were administered to a single host
without transplantation (Figure 5A). By the third
treatment tumours were almost totally resistant as
indicated by a lack of growth delay. However, there
could be several possible explanations of this
resistance. In addition to the possible selection of
inherently resistant tumour cells without the
complications of resistant cell loss at transplanta-
tion, which would tend to reduce the rate of
resistance development, the pharmacokinetics of the
drug may have changed. Induction of catabolising
enzymes in the mouse liver or elsewhere may reduce
the antitumour activity of the drug. However,244 T.C. STEPHENS et al.
extinction of resistant cells is still possible in this
style of experiment. In contrast, the activity of CY
was unchanged as indicated by a constant
substantial growth delay during four treatments
(Figure 5B).
In a previous paper we attempted, unsuccessfully,
to model mathematically the emergence of
resistance to melphalan in the MT carcinoma
during a retreatment protocol (McMillan et al.,
1985). Efforts to model our data also failed and it
seems to us that the ideas of Goldie & Coldman
(1979), and Skipper et al. (1978), may be too
simplistic to adequately fit real data.
The MeCCNU resistant subline, R4/1, was
characterised for cross-resistance to some other
agents. It was found to be cross-resistant with other
bifunctional nitrosoureas (CCNU and BCNU), but
not with the alkylating agents CY and melphalan,
the DNA cross-linking agent cis-Pt, or ionising
radiation. Although cross-resistance between nitro-
soureas, possibly due to enhanced 06-methyl-
guanine-DNA methyl transferase levels, is
commonly found, cross-resistance to CY (Skipper
et al., 1972) and melphalan (Burman & Steel, 1984)
have been reported in some tumour cell lines
although these agents do not react primarily at this
site in DNA.
We are currently attempting to establish more
clearly the mechanism of resistance to MeCCNU in
the majority of tumours, that does not appear to
involve permanent acquisition of a resistant
phenotype. Having shown that LL subline R4/1 has
increased ability to repair 06-alkylguanine lesions
of DNA (in preparation), we are considering the
testable hypothesis that transient increases in the
intracellular level of 06-methylguanine-DNA
methyltransferase may protect inherently sensitive
cells from killing by MeCCNU. We are not aware
of any other in vivo studies in which apparently
transient drug resistance has been reported, and this
may represent an important new type of drug
resistance.
We thank Dr G.G. Steel and Professor M.J. Peckham for
their helpful advice and criticism throughout this work.
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